Molecular Testing of Lymphoproliferative Disorders: Current Status and Perspectives

키워드

참고문헌 (92)

1. Tonegawa S, "Somatic generation of antibody diversity", Nature, 302, pp.575~581 (1983)
2. Davis MM, "T-cell antigen receptor genes and T-cell recognition", Nature, 334, pp.395~402 (1988)
3. van Dongen JJ, "Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936", Leukemia, 17, pp.2257~2317 (2003)
4. Gilfillan S, "Mice lacking TdT: mature animals with an immature lymphocyte repertoire", Science, 261, pp.1175~1178 (1993)
5. van Dongen JJ, "Leukemia", pp.85~130 (2002), WB Saunders Company
6. Langerak AW, "EuroClonality", BIOMED-2 guidelines for interpretation and reporting of Ig, Leukemia, pp.2012, 26[DOI]
7. Sherwood AM, "Deep sequencing of the human TCRγ and TCRβ repertoires suggests that TCRβ rearranges after αβ and γδ T cell commitment", Sci Transl Med, 3, pp.90~61 (2011)
8. Bailey NG, "Molecular diagnostics of T-cell lymphoproliferative disorders", Cancer J, 20, pp.48~60 (2014)
9. Schafernak KT, "Clonality assessment of cutaneous B-cell lymphoid proliferations: a comparison of flow cytometry immunophenotyping, molecular studies, and immunohistochemistry", in situ hybridization and review of the literature, 2014, pp.36, 781~795
10. FÖdinger M, "Combined polymerase chain reaction approach for clonality detection in lymphoid neoplasms", Diagn Mol Pathol, 8, pp.80~91 (1999)
11. Thériault C, "PCR analysis of immunoglobulin heavy chain (IgH) and TcR-γ chain gene rearrangements in the diagnosis of lymphoproliferative disorders: results of a study of 525 cases", Mod Pathol, 13, pp.1269~1279 (2000)
12. Benhattar J, "Improved polymerase chain reaction detection of clonal T-cell lymphoid neoplasms", Diagn Mol Pathol, 4, pp.108~112 (1995)
13. Signoretti S, "Detection of clonal T-cell receptor γ gene rearrangements in paraffin-embedded tissue by polymerase chain reaction and nonradioactive single-strand conformational polymorphism analysis", Am J Pathol, 154, pp.67~75 (1999)
14. Patel KP, "Comparison of BIOMED-2 versus laboratory-developed polymerase chain reaction assays for detecting T-cell receptor-γ gene rearrangements", J Mol Diagn, 12, pp.226~237 (2010)
15. van Krieken JH, "Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action BHM4-CT98-3936", Leukemia, 21, pp.201~206 (2007)
16. Langerak AW, "Polymerase chain reaction-based clonality testing in tissue samples with reactive lymphoproliferations: usefulness and pitfalls. A report of the BIOMED-2 Concerted Action BMH4-CT98-3936", Leukemia, 21, pp.222~229 (2007)
17. Brüggemann M, "Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936", Leukemia, 21, pp.215~221 (2007)
18. Kuppers R, "Cellular origin of human B-cell lymphomas", N Engl J Med, 341, pp.1520~1529 (1999)
19. Davis TH, "Detection of clonal immunoglobulin gene rearrangements by polymerase chain reaction amplification and single-strand conformational polymorphism analysis", Am J Pathol, 142, pp.1841~1847 (1993)
20. Bourguin A, "nonradioactive detection of clonal T-cell receptor gene rearrangements in lymphoid neoplasms", Proc Natl Acad Sci U S A, 87, pp.8536~8540 (1990)
21. Medeiros LJ, "Overview of the role of molecular methods in the diagnosis of malignant lymphomas", Arch Pathol Lab Med, 123, pp.1189~1207 (1999)
22. Boeckx N, "Fusion gene transcripts and Ig", TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia, 2002, pp.16, 368~375
23. Szczepanski T, "Cross-lineage T cell receptor gene rearrangements occur in more than ninety percent of childhood precursor-B acute lymphoblastic leukemias: alternative PCR targets for detection of minimal residual disease", Leukemia, 13, pp.196~205 (1999)
24. Szczepanski T, "Lymphoma with multi-gene rearrangement on the level of immunoglobulin heavy chain, light chain, and T-cell receptor β chain", Am J Hematol, 59, pp.99~100 (1998)
25. Moreau EJ, "Easy detection of all T cell receptor gamma (TCRG) gene rearrangements by Southern blot analysis: recommendations for optimal results", Leukemia, 13, pp.1620~1626 (1999)
26. Langerak AW, "Detection of T cell receptor beta (TCRB) gene rearrangement patterns in T cell malignancies by Southern blot analysis", Leukemia, 13, pp.965~974 (1999)
27. Kluin P, "Molecular cytogenetics of lymphoma: where do we stand in 2010", Histopathology, 58, pp.128~144 (2011)
28. Niitsu N, "Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24", c-MYC translocations, 2009, pp.23, 777~783
29. Johnson NA, "Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone", J Clin Oncol, 30, pp.3452~3459 (2012)
30. Horn H, "MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma", Blood, 121, pp.2253~2263 (2013)
31. Hu S, "MYC", BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program, 2013, pp.121, 4021~4031
32. Swerdlow SH, "The 2016 revision of the World Health Organization classification of lymphoid neoplasms", Blood, 127, pp.2375~2390 (2016)
33. Swerdlow SH, "WHO classification of tumours of haematopoietic and lymphoid tissues" (2008), IARC Press
34. Green TM, "Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone", J Clin Oncol, 30, pp.3460~3467 (2012)
35. Campbell LJ, "Cancer cytogenetics: methods and protocols" (2011), Humana Press
36. Wolff DJ, "Guidance for fluorescence in situ hybridization testing in hematologic disorders", J Mol Diagn, 9, pp.134~143 (2007)
37. McGowan-Jordan J, "ISCN 2016: an international system for human cytogenomic nomenclature" (2016), Karger
38. Alizadeh AA, "Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling", Nature, 403, pp.503~511 (2000)
39. Wright G, "A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma", Proc Natl Acad Sci U S A, 100, pp.9991~9996 (2003)
40. Testoni M, "Genetic lesions in diffuse large B-cell lymphomas", Ann Oncol, 26, pp.1069~1080 (2015)
41. Carbone A, "Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy", Ann Hematol, 93, pp.1263~1277 (2014)
42. Hans CP, "Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray", Blood, 103, pp.275~282 (2004)
43. Choi WW, "A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy", Clin Cancer Res, 15, pp.5494~5502 (2009)
44. Meyer PN, "Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab", J Clin Oncol, 29, pp.200~207 (2011)
45. Gutiérrez-García G, "Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy", Blood, 117, pp.4836~4843 (2011)
46. Intlekofer AM, "Precision therapy for lymphoma : current state and future directions", Nat Rev Clin Oncol, 11, pp.585~596 (2014)
47. Scott DW, "Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue", Blood, 123, pp.1214~1217 (2014)
48. Scott DW, "Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies", J Clin Oncol, 33, pp.2848~2856 (2015)
49. Dietrich S, "BRAF inhibition in hairy cell leukemia with low-dose vemurafenib", Blood, 127, pp.2847~2855 (2016)
50. Raess PW, "BRAF V600E is also seen in unclassifiable splenic B-cell lymphoma", leukemia, a potential mimic of hairy cell leukemia, 2013, pp.122, 3084~3085
51. Blombery PA, "Detection of BRAF mutations in patients with hairy cell leukemia and related lymphoproliferative disorders", Haematologica, 97, pp.780~783 (2012)
52. Arcaini L, "The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms", Blood, 119, pp.188~191 (2012)
53. Mason EF, "Detection of activating MAP2K1 mutations in atypical hairy cell leukemia and hairy cell leukemia variant", Leuk Lymphoma, 58, pp.233~236 (2017)
54. Waterfall JJ, "High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias", Nat Genet, 46, pp.8~10 (2014)
55. Prashant Kapoor, "Diagnosis and Management of Waldenström Macroglobulinemia", JAMA Oncology, 3(9), pp.1257~ (2017), American Medical Association (AMA)[DOI]
56. Schmidt J, "MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity", Br J Haematol, 169, pp.795~803 (2015)
57. Martinez-Lopez A, "MYD88 (L265P) somatic mutation in marginal zone B-cell lymphoma", Am J Surg Pathol, 39, pp.644~651 (2015)
58. Hamadeh F, "MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma", Mod Pathol, 28, pp.564~574 (2015)
59. Salaverria I, "Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults", Blood, 118, pp.139~147 (2011)
60. Salaverria I, "A recurrent 11q aberration pattern characterizes a subset of MYC-negative highgrade B-cell lymphomas resembling Burkitt lymphoma", Blood, 123, pp.1187~1198 (2014)
61. Ferreiro JF, "Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain", loss pattern, 2015, pp.100, e275~e279
62. Stilgenbauer S, "Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial", Blood, 123, pp.3247~3254 (2014)
63. Nadeu F, "Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia", Blood, 127, pp.2122~2130 (2016)
64. te Raa GD, "Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia", Leuk Lymphoma, 54, pp.1849~1853 (2013)
65. Rossi D, "Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia", Blood, 119, pp.2854~2862 (2012)
66. Beà S, "Landscape of somatic mutations and clonal evolution in mantle cell lymphoma", Proc Natl Acad Sci U S A, 110, pp.18250~18255 (2013)
67. Xu-Monette ZY, "Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study", Blood, 120, pp.3986~3996 (2012)
68. Cao Y, "Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors", Oncotarget, 7, pp.83294~83307 (2016)
69. Jardin F, "Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal Bcell lymphoma", Am J Hematol, 91, pp.923~930 (2016)
70. Camus V, "Detection and prognostic value of recurrent exportin 1 mutations in tumor and cellfree circulating DNA of patients with classical Hodgkin lymphoma", Haematologica, 101, pp.1094~1101 (2016)
71. Nakajima H, "TET2 as an epigenetic master regulator for normal and malignant hematopoiesis", Cancer Sci, 105, pp.1093~1099 (2014)
72. Lemonnier F, "Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters", Blood, 120, pp.1466~1469 (2012)
73. Young RM, "B-cell receptor signaling in diffuse large B-cell lymphoma", Semin Hematol, 52, pp.77~85 (2015)
74. Okosun J, "Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma", Nat Genet, 46, pp.176~181 (2014)
75. Bouska A, "Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma", Leukemia, 31, pp.83~91 (2017)
76. Younes A, "Promising novel agents for aggressive B-cell lymphoma", Hematol Oncol Clin North Am, 30, pp.1229~1237 (2016)
77. Kurmasheva RT, "Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the pediatric preclinical testing program", Pediatr Blood Cancer, 64, pp.e26218~ (2017)
78. Parrilla Castellar ER, "ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes", Blood, 124, pp.1473~1480 (2014)
79. King RL, "Morphologic features of ALKnegative anaplastic large cell lymphomas with DUSP22 rearrangements", Am J Surg Pathol, 40, pp.36~43 (2016)
80. Manso R, "The RHOA G17V gene mutation occurs frequently in peripheral T-cell lymphoma and is associated with a characteristic molecular signature", Blood, 123, pp.2893~2894 (2014)
81. Yoo HY, "A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma", Nat Genet, 46, pp.371~375 (2014)
82. Sakata-Yanagimoto M, "Somatic RHOA mutation in angioimmunoblastic T cell lymphoma", Nat Genet, 46, pp.171~175 (2014)
83. Palomero T, "Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas", Nat Genet, 46, pp.166~170 (2014)
84. Vallois D, "Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas", Blood, 128, pp.1490~1502 (2016)
85. Rohr J, "Recurrent activating mutations of CD28 in peripheral T-cell lymphomas", Leukemia, 30, pp.1062~1070 (2016)
86. Streubel B, "Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma", Leukemia, 20, pp.313~318 (2006)
87. Pechloff K, "The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma", J Exp Med, 207, pp.1031~1044 (2010)
88. Wang C, "IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic Tcell lymphoma", Blood, 126, pp.1741~1752 (2015)
89. Cairns RA, "IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma", Blood, 119, pp.1901~1903 (2012)
90. Jiang L, "Exome sequencing identifies somatic mutations of DDX3X in natural killer", T-cell lymphoma, 2015, pp.47, 1061~1066
91. Lee S, "Genetic alterations of JAK", STAT cascade and histone modification in extranodal NK, Oncotarget, pp.2015, 6[DOI]
92. Dobashi A, "Frequent BCOR aberrations in extranodal NK", T-cell lymphoma, nasal type, 2016, pp.55, 460~471

관련 논문AI추천